NVC-001 is designed to target the mechanobiological root cause of LMNA dilated cardiomyopathy and has disease-modifying potential SINGAPORE, PARIS and PHILADELPHIA, Oct. 8, 2026 /PRNewswire/ -- Nuevocor, a clinical-stage biotechnology company pioneering mechanobiology-targeted therapies designed to address the root causes of life-threatening cardiomyopathies, today announced that the first...
SINGAPORE, March 31, 2025 /PRNewswire/ -- Allozymes, a leader in protein engineering, and Bonumose, a leader in innovative enzyme combinations enabling the production of...
Endless Growth of Wealth: Reinvest Dividends into Micro-Investment Funds TAIPEI, March 31, 2025 /PRNewswire/ -- "Digital Hen" is a fund investment service jointly...
SUZHOU, China, March 31, 2025 /PRNewswire/ -- Amid frequent pro-fertility policy updates, Basecare Medical, a pioneer in the assisted reproductive IVD sector with full fertility...
SHANGHAI, March 31, 2025 /PRNewswire/ -- ATRenew Inc. ("ATRenew" or the "Company") (NYSE: RERE), a leading technology-driven platform for pre-owned consumer electronics transactions and...